Alzheimer’s is a relentless disease in which toxic clusters of beta-amyloid protein collect in brain cells. Now, scientists have designed a synthetic peptide, or small protein, that can block beta-amyloid in its early and most harmful stages.
The Risk of AIRA
Amyloid plaque are targeted and mobilized by anti-amyloid antibodies (such as lecanamab and donanamab). The antibody-bound plaque clear through the brain’s immune cells, called microglia, by binding Fc-gamma Receptors (FCgRs). (Alzheimers Dis Rep. 2023) This binding alters the microglia resulting in inflammation and cytokine storm and thereby creating a high risk of ARIA (https://ajronline.org/doi/epdf/10.2214/AJR.22.28461).